India's third largest drug-maker, Cipla Ltd, is reportedly eyeing its first commercial launch in the US around 2020. The company plans to build a pipeline of speciality drugs in the country.Cipla is planning to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments. With this move, the Mumba-headquartered firm aims to narrow the gap with its Indian competitors like Dr Reddy's, Sun Pharmaceuticals and Lupin. Previously the company has partnered leading generic companies such as Teva and US-based Invagen in a deal worth $550 million but remained relatively quiet in the world′s largest drug market.Umang Vora, Global COO at Cipla, said: "What we don′t want to happen is to try to catch up on the US generics piece now, and then five years later we again start to catch up on the speciality side of the business. As we begin to catch up on the US generics space, we are also ensuring attention to speciality business.”He said there is enough scope for the company to leapfrog and leverage its inherent technological capabilities with a thrust on the speciality side to narrow the gap with its local peers.Infosys buys stake in Trifacta
Infosys purchased a minority stake in US-based Trifacta Inc. for an undisclosed amount. The Indian software giant's investment in the data visualisation start-up came from the company's $500 million innovation fund.Ritika Suri, senior vice-president, corporate development, Infosys, said: "We see tremendous potential in self-service data preparation solutions like Trifacta to significantly help clients unlock the business value of their diverse and fast-growing Big Data assets."Adam Wilson, CEO of Trifacta, said: "We are thrilled to become a part of Infosys Information Platform and collaborate with Infosys as a key go-to-market partner. This partnership will play an important role in our global expansion, bringing the power and value of data wrangling to customers around the world."Trifacta is the second investment in a data-focused start-up by India's second largest software firm.Founded in 2012, Trifacta applies machine learning technologies to help data scientists understand data better.US, India collaborate on NIIF
The US government has extended its support to India for finding innovative ways to raise funds required to meet the country's need for modern infrastructure and create jobs.In a joint statement, the finance ministry counterparts of the two countries, Indian finance minister Arun Jaitely and US Treasury Secretary Jacob Lew, said: "We are working together to support India′s National Investment and Infrastructure Fund (NIIF) in order to increase financing options for India′s infrastructure growth.”The US-India Investment Initiative, launched last year, saw the two governments working in collaboration with the private sector to identify specific policies, regulations and technical collaboration to mobilise both domestic and foreign capital to build infrastructure and create jobs.Their joint statement further said public debt management is an area of focus for India. India believes in continued efforts for more efficient debt and cash management, as well as the development of a deeper and more robust domestic debt market.It presents an opportunity for India's Ministry of Finance and the US Treasury's Office of Technical Assistance to engage in knowledge and information sharing in India's government debt management program.